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Abstract
Background
The Core Outcome Measures in Effectiveness Trials (COMET) database is a publically
available, searchable repository of published and ongoing core outcome set (COS) studies.
An annual systematic review update is carried out to maintain the currency of database
content.
Methods
The methods used in the fourth update of the systematic review followed the same approach
used in the original review and previous updates. Studies were eligible for inclusion if they
reported the development of a COS, regardless of any restrictions by age, health condition
or setting. Searches were carried out in March 2018 to identify studies that had been pub-
lished or indexed between January 2017 and the end of December 2017.
Results
Forty-eight new studies, describing the development of 56 COS, were included. There has
been an increase in the number of studies clearly specifying the scope of the COS in terms
of the population (n = 43, 90%) and intervention (n = 48, 100%) characteristics. Public partic-
ipation has continued to rise with over half (n = 27, 56%) of studies in the current review
including input from members of the public. The rate of inclusion of all stakeholder groups
has increased, in particular participation from non-clinical research experts has risen from
32% (mean average in previous reviews) to 62% (n = 29). Input from participants located in
Australasia (n = 17; 41%), Asia (n = 18; 44%), South America (n = 13; 32%) and Africa (n =
7; 17%) have all increased since the previous reviews.
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Conclusion
This update included a pronounced increase in the number of new COS identified compared
to the previous three updates. There was an improvement in the reporting of the scope,
stakeholder participants and methods used. Furthermore, there has been an increase in
participation from Australasia, Asia, South America and Africa. These advancements are
reflective of the efforts made in recent years to raise awareness about the need for COS
development and uptake, as well as developments in COS methodology.
Introduction
Insufficient consideration of the outcomes measured in clinical trials, and other studies, is
increasingly being addressed through the development and use of core outcome sets (COS). A
COS is an agreed standardised set of outcomes that should be measured and reported, as a
minimum, in all trials for a specific clinical area [1]. The Core Outcome Measures in Effective-
ness Trials (COMET) Initiative aims to collate and stimulate the development and application
of COS, by maintaining a public repository of studies relevant to the development of COS
(The COMET database, http://www.comet-initiative.org/studies/search). A survey of users of
the database was undertaken to understand the reasons why people were searching the
COMET database [2]. The most frequent users were people thinking about developing a COS
to see whether a COS already exists in their area of interest to avoid any duplication, therefore
emphasising the importance of keeping the database current.
A systematic review was conducted to initially populate the COMET database [3], and it
has been subsequently updated annually to include all published COS up to, and including,
2016 [2, 4, 5]. The previous update showed that COS developers are adopting a more struc-
tured approach towards COS development, and public participation in COS development has
also increased [5]. The review, however, highlighted a gap in the involvement of stakeholders
from a wider range of geographical settings, in particular low and middle income countries
(LMIC). This is important to increase the applicability of COS to global health and tackling the
global burden of disease [6].
The database is therefore an integral resource to not only the development of COS, but also
to the uptake of COS in research and in the avoidance of unnecessary duplication and waste of
scarce resources. Eligible studies are added to the database as they are found; however, an addi-
tional annual update to the systematic review means that the database is kept up to date.
The aims of the current study were consistent with the previous update [5], specifically to:
(i) update the systematic review in order to identify any further studies where a COS has been
developed; (ii) to describe the methodological approaches taken in these studies, and (iii) to
highlight areas for future COS development and improvement.
Methods
Systematic review update
The methods used in this updated review followed the same approach used in the original
review [3] and previous updates [2, 4, 5]. The methods were described in detail previously [3,
5]; a summary of methods is provided below.
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Study selection
The inclusion and exclusion criteria were described in detail in the original systematic review
[3]. Studies were eligible for inclusion if they had applied methodology for determining which
outcome domains or outcomes should be measured in clinical trials or other forms of health
research. As described previously, studies were eligible for inclusion if they reported the devel-
opment of a COS, regardless of any restrictions by age, health condition or setting. Studies
describing the development of a Patient Reported Outcome (PRO) COS (a core set of patient-
reported symptoms and health related quality of life domains) or Core Event Set (a core set of
adverse events or complications) were eligible for inclusion in the review update. Studies
describing the update of an existing COS were included as linked papers to the original COS.
Identification of relevant studies
In March 2018, MEDLINE via Ovid and SCOPUS were searched without language restric-
tions. The search identified studies that had been published or indexed since the previous sys-
tematic review update, between January 2017 and the end of December 2017. The multifaceted
search strategy, developed for the original review using a combination of text words and index
terms, was used for the current update [3] (S1 Table). Ovid included a new search option enti-
tled ‘MEDALL’ that incorporates all previous search options and provides the most extensive
coverage, including the ‘in-process’ citations as well as E-pub ahead of print citations. This
search option was selected for this update of the systematic review in order to identify eligible
studies at the earliest possible opportunity.
Hand searching was completed, including any studies that had been submitted directly to
the COMET database, references cited in eligible studies, as well as those in ineligible studies
that referred to or used a COS.
Selecting studies for inclusion in the review
As described previously [3, 5], records from each database were combined and duplicates
removed. Titles and abstracts were read to assess eligibility of studies for inclusion in the
review (stage 1). Full texts of potentially relevant articles were obtained to assess for inclusion
(stage 2). Two of five reviewers (EG, SG, NH, VS and KMS) independently checked the title
and abstract of each citation. Citations were retained for further checking if agreement could
not be reached. Two of the same five reviewers assessed each full paper for inclusion in the
review. In cases of disagreement a third reviewer was consulted. The reasons for exclusion at
this stage were documented for articles judged to be ineligible.
Checking for agreement between reviewers
One reviewer was new to this systematic review and had not been involved in previous updates
(KMS). During each stage of the review process, agreement between KMS and the lead
reviewer (EG) was assessed prior to independently assessing records. Agreement between all
other reviewers had been checked in previous updates.
Checking for correct exclusion
At abstract stage. A 1% sample of the records excluded on the basis of the title and
abstract was checked by a sixth reviewer (Jamie Kirkham) and assessed for correct exclusion. If
any studies were identified as being incorrectly excluded, further checking was performed
within the other excluded records.
Fourth annual update to a systematic review of core outcome sets for research
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At full text stage. Of the records that had been excluded after reading the full text, 5%
were assessed for correct exclusion. If any studies were identified as being incorrectly excluded
at this stage, further checking was performed.
Data extraction
Described in full previously [3], data were extracted in relation to the study aim(s), health area,
target population, interventions covered, methods of COS development and stakeholder
groups involved. Data relating to the geographical locations of participants included in the
development of COS were also extracted.
Data analysis and presentation of results
We report the review in accordance with PRISMA guidelines [7] (S1 File). We describe the
studies narratively, and present the findings in text and tables. As in previous updates, we did
not anticipate conducting any statistical analyses to combine the findings.
Results
Description of studies
Following the removal of duplicates, 5140 records were identified in the database search. A
total of 4626 records were excluded during the title and abstract stage, and a further 444 were
excluded following the assessment of full text (Fig 1). Table 1 provides a summary of the rea-
sons for exclusion of records at full text stage. Seventy records related to 45 new studies that
met the inclusion criteria. In addition to the review search, three additional records were iden-
tified through database search alerts as being eligible for inclusion in the review. These three
studies were not identified during the review search, as although they were published in 2017,
they had not been indexed in the databases at the time we ran our search. A further 15 reports
were identified by hand searching references of included studies. In total, 88 reports relating to
48 new studies describing the development of 56 COS were included for the first time in this
update (S2 Table).
Included studies
Year of publication. The year of first publication of COS has been updated to include the
48 new studies included in this update (Fig 2). Of the 48 studies identified in this update, 36
were published in 2017, 11 were published in 2016 and one study was published in 2015.
Scope of core outcome sets. The scope of published COS studies is summarised in
Table 2. This includes study aims, setting for intended use, population characteristics and
intervention characteristics. Table 2 highlights that there has been an increase in the number
of COS studies specifying the population (n = 43, 90%) and intervention (n = 48, 100%) char-
acteristics of the newly developed COS. Fig 3 displays the number of COS that have been
developed in each disease category. The majority of COS have been developed within the areas
of cancer, rheumatology, heart & circulation, neurology and orthopaedics & trauma. Disease
categories and disease names are provided in S2 Table.
Methods used to select outcomes. The methods used to develop the 48 new COS identi-
fied in the current review are presented in Table 3 alongside the methods used in the four pre-
vious systematic reviews. Table 3 highlights that the use of mixed methods to develop a COS
has remained high (n = 35; 73%). The use of the Delphi technique has also remained high with
48% (n = 23) of studies using the technique in combination with other methods.
Fourth annual update to a systematic review of core outcome sets for research
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People involved in selecting outcomes. The list of stakeholders included in COS develop-
ment (Table 4) has been updated to include the COS identified in this update. Of the 307 pub-
lished COS studies, 273 (89%) provided information about the stakeholders who participated
in the COS development. Clinical experts were included in 268 (98%) studies; this is in direct
contrast to public representatives who were included in 89 (33%) studies. Public participation
has continued to rise in recent years, with 56% (n = 27) of studies in the current review includ-
ing input from members of the public. The rate of inclusion of all stakeholder groups has
increased in comparison to the original review and previous review updates, with participation
from non-clinical research experts, in particular, rising from 32% (n = 73) as the mean average
in previous reviews to 62% (n = 29) in the current review.
As described previously [3, 5], public representatives include patients, carers, health and
social care service users and people from organisations who represent these groups. The degree
of public participation within the development of the COS studies included in this updated
review is described in Table 5. All of the 27 studies that reported including public participants
provided some detail about their participation. Among Delphi studies that reported participa-
tion of both clinical experts and the public, levels of participation for public participants ran-
ged from 6% [8] to 69% [9].
Table 6 lists the geographical locations, by continent, of the participants involved in devel-
oping the COS in this update and in the combined reviews, as reported by the included studies.
In the current review, participant locations were provided in 41 of the 48 studies, however for
the remaining seven studies, location information was only provided for the authors. The
majority of COS were developed with the inclusion of participants located in Europe (n = 38;
Fig 1. Identification of studies.
https://doi.org/10.1371/journal.pone.0209869.g001
Table 1. Reasons for exclusion at full text stage.
Exclusion Categories of Full Text Stage Number of
records
Studies relating to how, rather than which, outcomes should be measured 50
Studies reporting the design/ rationale of single trial 3
Studies reporting the use of a COS 1
Systematic reviews of clinical trials 39
Review/overview/discussion only, no outcome recommendations 113
Core outcomes/ outcome recommendations not made 72
Quality indicators 5
One outcome/ domain only 8
Instrument development 8
Recommendations by single author only 2
ICF Core set 1
Preclinical/ Early phase only (0, I, II) 8
Irrelevant 43
Assessed in previous review 3
ICF Core set development 2
HRQL 3
Recommendations for clinical management in practice not research 61
Studies that elicit stakeholder group opinion regarding which outcome domains or outcomes
are important
8
Ongoing studies 14
https://doi.org/10.1371/journal.pone.0209869.t001
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93%) and North America (n = 28; 68%). However, input from participants located in Austral-
asia (n = 17; 41%), Asia (n = 18; 44%), South America (n = 13; 32%) and Africa (n = 7; 17%)
has increased since the previous reviews. The number of countries that have been involved in
the development of a COS ranges from 1 to 76 (a median of 6).
Discussion
This systematic review update has identified 48 new COS articles that describe 56 new COS.
This is a marked increase in the number of new COS identified in the previous three updates,
which included 28, 20 and 15 new COS publications (describing the development of 29, 20
and 15 COS) respectively [2, 4, 5]. Similarly, there has been a continued increase in COMET
website and database visits, new visitors, number of database searches and visits from around
the world in 2017 (Source of data usage: Google Analytics), with 24,884 visits; 15,546 new visi-
tors; 5142 database searches, and visitors from 139 countries. The sustained growth in use sug-
gests that the COMET website and database are continuing to raise awareness about the
existence of, and need for, COS; which could explain this increase in the number of COS pub-
lished in 2017 and subsequently included in this review. Their inclusion in the database brings
the overall total of COS publications to 307, relating to 366 COS.
This review has identified an improvement in the reporting of COS scope (population and
intervention characteristics), stakeholder participants and methods used. Core Outcome Set-
STAndards for Reporting (COS-STAR) were published in 2016 [10]. This is the first update
since the publication of the COS-STAR guidelines, and it is encouraging to see that ten of the
48 studies (21%) included in this update referenced these reporting guidelines. This provides a
baseline with which to compare future updates, where we hope to see a continued increase in
the number of studies reporting their work using these guidelines.
Fig 2. Year of first publication of each COS study (n = 307).
https://doi.org/10.1371/journal.pone.0209869.g002
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The previous update highlighted an increase in the use of mixed methods, including the
Delphi method, for COS development [5]. A recent survey of ongoing COS developers indi-
cated that mixed methods, including Delphi, were commonly used in ongoing COS develop-
ment, and there is an increased inclusion of public participants in ongoing studies [11]. As
such, the percentage of new studies including public participation is expected to rise in future
updates of this systematic review as ongoing studies are published. Participation of non-clini-
cal research experts has increased, and as one of the criteria included in the recently published
minimum standards for COS development [12], we would expect that this should continue to
increase in new COS studies included in any further updates to this review. The Core Outcome
Set-STAndards for Development (COS-STAD) recommendations will help users to assess
whether a particular COS has been developed using a reasonable approach.
The involvement of stakeholders from a range of countries, but in particular lower and
middle income countries, has previously been identified as a gap in COS development. [5]
This update has shown an increase in participation from Australasia, Asia, South America and
Africa. A recent survey to identify the top priorities for trials methodology research in LMICs
Table 2. The scope of included studies (n = 307).
Original
review
n (%)
Update review
1
n (%)
Update review
2
n (%)
Update review 3 n
(%)
Update review 4 n
(%)
Combined�
N (%)
Study aims
Specifically considered outcome selection and
measurement
98 (50) 21 (75) 13 (65) 10 (60) 33 (69) 175 (57)
Considered outcomes while addressing wider clinical trial
design issues
98 (50) 7 (25) 7 (35) 5 (40) 15 (31) 132 (43)
Intended use of recommendations
Clinical research 174 (89) 24 (86) 19 (95) 9 (60) 44 (92) 270 (88)
Clinical research and practice 22 (11) 4 (14) 1 (5) 6 (40) 4 (8) 37 (12)
Population characteristics
Adults 12 (6) 12 (43) 5 (25) 10 (67) 21 (44) 63 (21)
Children 22 (11) 2 (7) 6 (30) 0 (0) 5 (10) 35 (11)
Adults and children 12 (6) 2 (7) 0 (0) 3 (20) 10 (21) 27 (9)
Older adults 2 (1) 1 (4) 0 (0) 0 (0) 3 (6) 6 (2)
Adolescents and adults 0 (0) 0 (0) 0 (0) 1 (7) 4 (8) 5 (2)
Not specified 148 (76) 11 (39) 9 (45) 2 (13) 5 (10) 171 (56)
Intervention characteristics
All intervention types 7 (4) 8 (29) 12 (60) 8 (53) 29 (60) 68 (22)
Drug treatments 39 (20) 4 (14) 0 (0) 0 (0) 4 (8) 46 (15)
Surgery 13 (7) 4 (14) 4 (20) 4 (27) 7 (15) 32 (10)
Vaccine 2 (1) 0 (0) 0 (0) 0 (0) 0 2 (1)
Rehabilitation 1 (1) 1 (4) 0 (0) 1 (7) 2 (4) 5 (2)
Exercise 1 (1) 1 (4) 1 (5) 0 (0) 1 (2) 4 (1)
Exercise (physical activity) 1 0 1 0 1
Exercise (yoga) 0 1 0 0 0
Procedure 4 (2) 0 (0) 2 (10) 0 (0) 2 (4) 8 (3)
Device 3 (2) 0 (0) 0 (0) 1 (7) 0 4 (1)
Other 11 (6) 5 (18) 0 (0) 1 (7) 3 (6) 20 (7)
Not specified 115 (59) 5 (18) 1 (5) 0 (0) 0 118 (38)
�Additional information provided by updated papers linked to previously published COS are reflected in the combined column.
https://doi.org/10.1371/journal.pone.0209869.t002
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Fig 3. Number of COS developed in each disease category (n = 307).
https://doi.org/10.1371/journal.pone.0209869.g003
Table 3. The methods used to develop COS (n = 307).
Main methods Original review n (%) Update review 1 n (%) Update review 2 n (%) Update review 3 n (%) Update review 4
n (%)
Combined�
N (%)
Semi-structured group discussion only 55 (28) 2 (7) 2 (10) 0 (0) 3 (6) 62 (20)
Unstructured group discussion only 18 (9) 0 (0) 0 (0) 0 (0) 0 (0) 18 (6)
Consensus development conference only 12 (6) 0 (0) 1 (5) 0 (0) 1 (2) 14 (5)
Literature/systematic review only 11 (6) 5 (18) 2 (10) 1 (7) 6 (13) 25 (8)
Delphi only 6 (3) 2 (7) 2 (10) 0 (0) 0 (0) 10 (3)
Survey only 3 (2) 0 (0) 0 (0) 0 (0) 1 (2) 4 (1)
NGT only 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1)
Interview only 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 1 (<1)
Mixed methods (see descriptions below) 74 (38) 17 (61) 13 (65) 12 (80) 35 (73) 151 (49)
Delphi + another method(s) 22 (11) 6 (21) 9 (45) 9 (60) 23 (48) 71 (23)
Semi-structured group discussion + another method(s) 30 (15) 7 (25) 4 (20) 2 (13) 9 (19) 51 (17)
Consensus development conference + another method(s) 7 (4) 0 (0) 0 (0) 0 (0) 1 (2) 8 (3)
Literature/systematic review + another method(s) 10 (5) 4 (14) 0 (0) 1 (7) 2 (4) 16 (5)
NGT + another method(s) 4 (2) 0 (0) 0 (0) 0 (0) 0 (0) 4 (1)
Focus group + another method(s) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1)
No methods described 16 (8) 2 (7) 0 (0) 2 (13) 1 (2) 21 (7)
�Additional information provided by updated papers linked to previously published COS are reflected in the combined column.
https://doi.org/10.1371/journal.pone.0209869.t003
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Table 4. Participant groups involved in selecting outcomes for inclusion in COS (n = 307).
Participants
category
Sub-category (not mutually exclusive) Frequency of participants
Original
review
n (%)
Update review
1
n (%)
Update review
2
n (%)
Update review
3
n (%)
Update review
4
n (%)
Combined^
N (%)
Clinical experts 171 (99) 20 (95) 17 (100) 14 (93) 46 (96) 268 (98)
Clinical experts 86 14 16 14 38 (79) 169 (62)
Clinical research expertise 66 9 9 2 26 (54) 114 (42)
Clinical trialists/ Members of a clinical trial
network
9 2 1 (2) 12 (4)
Others with assumptions� 54 54 (20)
Public representatives 30 (17) 13 (62) 11 (65) 8 (53) 27 (56) 89 (33)
Patients 19 11 7 8 18 (38) 63 (23)
Carers 7 1 3 3 9 (19) 23 (8)
Patient support group representatives 9 1 4 9 (19) 24 (9)
Service users 2 1 2 (4) 5 (2)
Non-clinical research experts 53 (31) 9 (43) 9 (53) 2 (13) 29 (60) 103 (38)
Researchers 26 4 4 2 26 (54) 64 (23)
Statisticians 19 4 3 1 (2) 27 (10)
Epidemiologists 11 2 1 4 (8) 19 (7)
Academic research representatives 4 4 (2)
Methodologists 6 3 2 4 (8) 16 (6)
Economists 3 1 2 (4) 6 (2)
Authorities 39 (23) 5 (24) 3 (18) 0 (0) 12 (25) 59 (22)
Regulatory agency representatives 30 4 3 6 (13) 43 (16)
Governmental agencies 12 1 5 (10) 18 (7)
Policy makers 4 1 3 (6) 8 (3)
Charities 1 1 (2) 2 (1)
Service commissioners 3 (6) 3 (1)
Industry representatives 31 (18) 4 (19) 3 (18) 0 (0) 9 (19) 47 (17)
Pharmaceutical industry representatives 28 3 3 8 (17) 42 (15)
Device manufacturers 2 1 1 (2) 4 (2)
Biotechnology company representatives 1 1 (<1)
Others 72 (42) 2 (10) 1 (6) 1 (7) 8 (17) 84 (31)
Service providers 4 (8) 4 (2)
Ethicists 1 1 (<1)
Journal editors 2 1 2 (4) 5 (2)
Funding bodies 1 1 (<1)
Yoga therapists/ instructors 1 1 (<1)
Members of health care transition research
consortium
1 1 (<1)
Educationalist 1 (2) 1 (<1)
Nutritionist 1 (2) 1 (<1)
National professional and academic bodies/
committees
1 (2) 1 (<1)
Others�� (besides known participants) 15 15 (6)
Others with assumptions� 54 54 (20)
(Continued)
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Table 4. (Continued)
Participants
category
Sub-category (not mutually exclusive) Frequency of participants
Original
review
n (%)
Update review
1
n (%)
Update review
2
n (%)
Update review
3
n (%)
Update review
4
n (%)
Combined^
N (%)
No details given 24 (12) 7 (25) 3 (15) 0 (0) 0 (0) 34 (11)
� 54 studies with clinical input but unclear about involvement of other stakeholders
�� Workshop/meeting participants (�5), subcommittee/committee (�2), guidelines panel, military personnel, moderator and audience, representatives from EORTC,
members with expertise in information technologies, informatics, clinical registries, data-standards development, expertise in vaccine safety, malaria control and
representatives from funding agencies/registration authorities, and donor organisation, members of the Rheumatology Section of the American Academy of Pediatrics,
the Pediatric Section of the ACR, and the Arthritis Foundation, the diagnostic radiology and basic science communities, and from individuals conversant with
functional and quality of life (QOL) assessments, comparative effectiveness research, and cost/ benefit analysis
^Additional information provided by updated papers linked to previously published COS are reflected in the combined column
https://doi.org/10.1371/journal.pone.0209869.t004
Table 5. Nature of patient participation where detail is reported (n = 27).
Methods used Total number of
participants
Number of public
participants
% Public participants when multiple stakeholder groups
included
Agiostratidou Survey Not reported 8 Unknown
Allin Delphi Round 1: 108 Round 1: 61 57%
Round 2: 96 Round 2: 51 53%
Round 3: 89 Round 3: 46 52%
Consensus meeting 17 6 35%
Measurement meeting 14 4 29%
Ammendolia Interviews� 28 28
Avery Interviews 38 31 82%
Delphi Round 1: 188 Round 1: 116 62%
Round 2: 161 Round 2: 94 58%
Consensus meeting� 20 20
Benstoem Delphi Round 1: 86 Round 1: NR 16%
Round 2: 46 Round 2: NR 16%
Round 3: 39 Round 3: NR 16%
Byrne Delphi Round 1: 132 Round 1: 34 26%
Round 2: 81 Round 2: 17 21%
Consensus meeting 12 3 25%
de Graaf Interviews� 26 26
Delphi^ Round 1: 126 Round 1: 0
Round 2: 97 Round 2: 0
Egan Delphi Round 1: 151 Round 1: 20 13%
Round 2: 120 Round 2: NR Unknown
Round 3: 101 Round 3: NR Unknown
Consensus meeting 14 2 14%
Grieve Workshops (x4) W1: 27 W1: 5 19%
W2: 15 W2: 1 7%
W3: 20 W3: 5 25%
W4: 18 W4: 3 17%
Klokkerud Delphi consensus meeting 46 6 13%
Layton Delphi Round 1: 500 Round 1: 307 61%
(Continued)
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Table 5. (Continued)
Methods used Total number of
participants
Number of public
participants
% Public participants when multiple stakeholder groups
included
Round 2: 164 Round 2: 52 32%
Round 3: 116 Round 3: 34 29%
MacLennan Interviews� 15 15
Delphi Round 1: 174 Round 1: 118 68%
Round 2: 158 Round 2: 109 69%
Round 3: 152 Round 3: 105 69%
Meeting 21 8 38%
Marrie Survey 296 20 7%
Workshop Not reported Not reported unknown
McNamara Delphi 17 1 6%
Millar Focus groups 72 14 19%
Interviews^ 13 0
Delphi Round 1: 19 Round 1: 2 11%
Round 2: 18 Round 2: NR
Nabbout Interviews 11 7 64%
Delphi^ Round 1: 8 Round 1: 0
Round 2: 7 Round 2: 0
Nikiphorou Workshops and
teleconference
26 2 8%
Obbarius Delphi 24 2 8%
Interviews not reported not reported
Ong Focus groups� 8 8
Survey� 1225 1225
Delphi not reported not reported
Page Delphi Round 1: 91 Round 1: 41 45%
Round 2: 96 Round 2: 41 43%
Sreih Delphi^ 99 0
Interviews/focus groups� 31 31
Steutel Delphi Round 1: 188 Round 1: 55
Round 2: 97 Round 2: 43
Meeting^ not reported 0
Tong NGT/focus groups� 57 57
Delphi Round 1: 1018 Round 1: 461 45%
Round 2: 844 Round 2: 387 46%
Round 3: 779 Round 3: 360 46%
Workshops 124 27 22%
Turnbull Survey 279 158 57%
Delphi 77 19 25%
Interviews� 48 48
Survey^ 178 0
Meeting^ 129 0
van der Poel Delphi^ Round 1: 30 Round 1: 30
Round 2: 30 Round 2: 30
Consensus meeting 16 1 6%
Wallace NGT� 68 68
Delphi^ Round 1: 318 Round 1: 0
(Continued)
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found that choosing appropriate outcomes to measure was one of the two most important top-
ics [6]. The involvement of LMIC countries in COS development and uptake is therefore a key
area of importance and efforts should be made to improve this.
In conclusion, we have completed the fourth update to a systematic review of COS, identify-
ing COS published and indexed in 2017. COS methodology, and consensus development
methodology more generally, have developed over recent years. This is reflected in the
improvements seen throughout these updates, not only in the reporting of important COS
details (such as scope), but in the methods chosen for development and the stakeholders who
participate in the process. With the recent development and publication of guidelines and
minimum standards for COS development [1, 12], it is hoped that improvements in these
areas will continue.
Supporting information
S1 File. PRISMA Checklist. PRISMA checklist for content of a systematic review.
(DOC)
Table 5. (Continued)
Methods used Total number of
participants
Number of public
participants
% Public participants when multiple stakeholder groups
included
Round 2: 153 Round 2: 0
Round 3: 137 Round 3: 0
Delphi^^ Round 1: 72 Round 1: 0
Round 2: 63 Round 2: 0
Round 3: 61 Round 3: 0
Webster Focus groups� 18 18
Consensus conference^ 27 0
Consensus conference^ 27 0
�patient only.
^clinician only.
^^researcher only.
https://doi.org/10.1371/journal.pone.0209869.t005
Table 6. Geographical locations of participants included in the development of each COS (n = 256).
Locations Original review
n (%)
Update review 1
n (%)
Update review 2
n (%)
Update review 3
n (%)
Update review 4
n (%)
Combined�
N (%)
North America 134 (82) 17 (68) 9 (64) 6 (55) 28 (68) 196 (77)
Europe 125 (76) 19 (76) 13 (93) 10 (91) 38 (93) 206 (81)
Australasia 42 (26) 4 (16) 5 (36) 3 (27) 17 (41) 74 (29)
Asia 34 (21) 3 (12) 6 (43) 1 (9) 18 (44) 63 (25)
South America 16 (10) 3 (12) 2 (14) 1 (9) 13 (32) 37 (15)
Africa 10 (6) 1 (4) 2 (14) 1 (9) 7 (17) 22 (9)
Total 164 (84) 25 (89) 14 (70) 11 (73) 41 (85) 256 (83)
No details provided 32 (16) 3 (11) 6 (30) 4 (27) 7 (15) 51 (17)
Median and range of number of countries 6, 1–76 2, 1–33 6, 1–28 2, 1–18 6, 1–37 6, 1–76
�Additional information provided by updated papers linked to previously published COS are reflected in the combined column.
https://doi.org/10.1371/journal.pone.0209869.t006
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S1 Table. Search strategy.
(DOCX)
S2 Table. Table of reports included in updated review (n = 88).
(DOCX)
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